Company / Cash & Equivalents
Maze Therapeutics, Inc. Cash & Equivalents History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$189.2M
FY2025
5-year range
$189.2M / $189.2M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#92 of 207
Health Care
What the data says
At $189M, Maze Therapeutics, Inc.'s cash & equivalents ranks #92 of 207 in the Health Care sector.
Based on SEC 10-K filings.
$189M in FY2025.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#92 of 207 in Health CareTop 44% of 207This company $189.2M Sector average $669.5M
▼
-71.7% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $189.2M | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026